ONWARD® Medical will host a webcast to share details of your

Nature Medicine published results from pivotal Up-LIFT trial

The company will discuss key trial results during this week’s webcast with company leaders and principal investigators and study participants.

EINDHOVEN, Netherlands, May 21, 2024 (GLOBE NEWSWIRE) — ONWARD Medical NV (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function and independence in people with spinal cord injury (SCI), today announces that on Thursday, May 23third At 2:30 pm CET/8:30 am ET, following a brief first quarter business update, CEO Dave Marver will host a discussion on the pivotal results of the Up-LIFT trial with a panel of leaders from the company, principal investigators of the study and participants of the study. The Up-LIFT trial demonstrated the safety and effectiveness of external ARC-EX therapy in improving hand and arm function after spinal cord injury.

Panelists will include Up-LIFT principal investigators Drs. Jim Guest, Chet Moritz and Candace Tefertiller, trial participants Sherown Campbell and Jessie Owen, and ONWARD Medical Vice President Clinical, Regulatory and Quality Erika Ross Ellison.

To join the webcast via Zoom, register using this link.

Participants will also be able to join by phone:

+32 2 290 9360 (Belgium)

+33 1 7037 2246 (France)

+49 69 3807 9884 (Germany)

+31 20 794 0854 (Netherlands)

+41 22 591 0156 (Switzerland)

+44 203 481 5240 (United Kingdom)

+1 346 248 7799 (USA)

Additional phone numbers available

Meeting ID: 879 5741 2479

A recording of the webcast will be available on the Company’s website following the live event.

To learn more about ONWARD Medical’s commitment to partnering with the SCI community to develop innovative solutions to restore movement, function and independence after a spinal cord injury, visit ONWD.com.

*Everything FORWARD® Medical devices and therapies, including but not limited to ARC-IM®ARCH-EX®ARC-BCI™and ARC™ Therapyalone or in combination with a brain-computer interface (BCI), they are investigational and not available for commercial use.

About ONWARD Medical

FORWARD® Medical is a medical technology company that creates therapies to restore movement, function and independence in people with spinal cord injury (SCI) and movement disabilities. Building on more than a decade of scientific discovery, preclinical and clinical research conducted in leading hospitals, rehabilitation clinics and neuroscience laboratories, the company has developed ARC Therapy™, which has received ten breakthrough device designations from the Food Administration. and Drug Administration (FDA).

ONWARD ARC therapy is a programmed, targeted spinal cord stimulation designed to be delivered by the company’s external ARC-EX.® o implantable ARC-IM® platforms. ARC therapy can also be delivered through the company’s ARC-BCI™ platform, which combines the ARC-IM system with brain-computer interface (BCI) technology to restore movement after spinal cord injury with thought-based control .

The use of non-invasive ARC-EX therapy significantly improved upper extremity function after SCI in the global pivotal Up-LIFT trial, the results of which were published by Nature medicine in May 2024. The company submitted its regulatory application to the FDA for approval of the ARC-EX system in the US and is preparing for regulatory submission in Europe. In parallel, the company is conducting clinical studies with its ARC-IM therapy, which demonstrated positive interim clinical results for better blood pressure regulation after spinal cord injury. Other ongoing clinical studies focus on the use of ARC-IM therapy to address mobility after SCI and gait challenges in Parkinson’s disease, as well as the use of the ARC-BCI platform to restore mobility. Thought-driven movement of the upper and lower extremities after SCI.

ONWARD Medical, headquartered in Eindhoven, Netherlands, has a science and engineering center in Lausanne, Switzerland, and a US office in Boston, Massachusetts. The company is listed on Euronext Brussels and Amsterdam (ticker: ONWD).

For more information, visit ONWD.com and connect with us on LinkedIn and YouTube.

For media inquiries:
Aditi Roy, Vice President of Communications
[email protected]

For investor inquiries:
Amori Fraser, Chief Financial Officer
[email protected]

Disclaimer

Certain statements, beliefs and opinions contained in this press release are forward-looking and reflect the current expectations and projections of the Company or, as applicable, the Company’s directors about future events. By their nature, forward-looking statements involve various risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors, including, but not limited to, changes in demand, competition and technology, may cause actual events, performance or results to differ materially from any anticipated developments. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances in which base these forward-looking statements. Neither the Company nor its advisors or representatives nor any of its subsidiaries nor the officers or employees of any such person guarantee that the assumptions underlying such forward-looking statements will be free of error nor accept any responsibility for the future accuracy of the forward-looking statements. statements contained in this press release or the actual occurrence of anticipated events. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. All ONWARD Medical devices and therapies referenced herein, including but not limited to ARC-IM®ARCH-EX®ARC-BCI™ and ARC Therapy™ are investigational and not available for commercial use.